GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » Price-to-Tangible-Book

Liquidia (Liquidia) Price-to-Tangible-Book : 13.78 (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Liquidia Price-to-Tangible-Book?

As of today (2024-06-05), Liquidia's share price is $14.26. Liquidia's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $1.04. Hence, Liquidia's Price to Tangible Book Ratio of today is 13.78.

The historical rank and industry rank for Liquidia's Price-to-Tangible-Book or its related term are showing as below:

LQDA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.07   Med: 4.96   Max: 26.9
Current: 13.71

During the past 8 years, Liquidia's highest Price to Tangible Book Ratio was 26.90. The lowest was 2.07. And the median was 4.96.

LQDA's Price-to-Tangible-Book is ranked worse than
92.63% of 1221 companies
in the Biotechnology industry
Industry Median: 2.78 vs LQDA: 13.71

A closely related ratio is called PB Ratio. As of today, Liquidia's share price is $14.26. Liquidia's Book Value per Sharefor the quarter that ended in Mar. 2024 was $1.13. Hence, Liquidia's P/B Ratio of today is 12.61.


Liquidia Price-to-Tangible-Book Historical Data

The historical data trend for Liquidia's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Price-to-Tangible-Book Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial 3.46 2.07 4.47 4.96 20.67

Liquidia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.03 9.55 10.13 20.67 14.25

Competitive Comparison of Liquidia's Price-to-Tangible-Book

For the Biotechnology subindustry, Liquidia's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Liquidia's Price-to-Tangible-Book falls into.



Liquidia Price-to-Tangible-Book Calculation

Liquidia's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=14.26/1.035
=13.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Liquidia Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Liquidia's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia (Liquidia) Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Executives
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs director
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880